ArticleJournal of the American Heart Association2025
Associations Between Plasma Omega-3 and Fish Oil Use With Risk of Atrial Fibrillation in the UK Biobank.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effects of Omega-3 Fatty Acid Treatment on Risk for Atrial Fibrillation: An Updated Meta-Analysis of 35 Trials including 114 592 Individuals.Circulation. Arrhythmia and electrophysiology · 2026Pooled it
- Association Between Plasma Omega-3 and Omega-6 Fatty Acid Levels and Atrial Fibrillation: A Large-Scale, Real-World Retrospective Study in Japan.Journal of atherosclerosis and thrombosis · 2026Article
- Review
- The Omega-3 Index and Self-Reported Dietary Intake of DHA and EPA in Highly Trained, Elite and World Class (Tier 3-5) Male and Female Athletes: An Australian Based Cross-sectional Study.Sports medicine - open · 2026Article
- Fish oil supplements in patients with chronic kidney disease.Clinical kidney journal · 2026Review
- Effects of Omega-3 Fatty Acid Treatment on Risk for Atrial Fibrillation: An Updated Meta-Analysis of 34 Trials including 114,326 Individuals.medRxiv : the preprint server for health sciences · 2025Article
- N-3 Fatty Acids (EPA and DHA) and Cardiovascular Health - Updated Review of Mechanisms and Clinical Outcomes.Current atherosclerosis reports · 2025Review
Corrections and comments
- Update of
Authors and funding
6 authors.
Funding
Abstract
backgroundMeta-analyses of randomized trials with omega-3 products found an increased risk of atrial fibrillation (AF), and a recent study from the UK Biobank concluded that fish oil supplement (FOS) use was likewise associated with increased risk of AF. Conversely, a meta-analysis based on blood levels of omega-3 fatty acids found an inverse relationship with AF risk. Thus, the relationship between omega-3 fatty acids and risk of AF remains unclear.
methodsWe conducted a retrospective analysis of UK Biobank data to link both plasma omega-3 levels and reported FOS use with AF risk. Among participants without prevalent AF, a random sample of 261 108 had data on plasma omega-3 levels and 466 169 reported about FOS use. The primary outcome was incident AF during follow-up (median, 12.7 years). Multivariable-adjusted hazard ratios (HRs [95% CIs]) for fatty acids were computed continuously (per interquintile range [IQ
resultsPlasma omega-3 levels were inversely associated with incident AF (HR per IQ
conclusionsHigher circulating omega-3 levels were linked to reduced AF risk in the UK Biobank. Further, after age was adjusted for as a continuous variable (as opposed to a dichotomous variable as in an earlier report), no association was found between FOS use and risk for AF.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.